Publication: 748

Publication: 748

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: J Clin Oncol vol 31 (7) 923-929

Year:: 2013
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 2

Parents:: 378 379 987
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:

Corr. Author:
Authors:: Eyal C. Attar Jeffrey L. Johnson Philip C. Amrein Gerard Lozanski Martha Wadleigh Daniel J. DeAngelo Jonathan E. Kolitz Bayard L. Powell Peter Voorhees Eunice S. Wang William Blum Richard M. Stone Guido Marcucci Clara D. Bloomfield Barry Moser Richard A. Larson

Networks:

Study: CALGB-10502
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 1/2

Keywords:: Hema5, Hema6, Original Reports, Hematologic Malignancy